Stock of the Day: Repligen Corporation Has Another Very Strong Trading Session

Stock of the Day: Repligen Corporation Has Another Very Strong Trading Session

The stock of Repligen Corporation (NASDAQ:RGEN) is a huge mover today! The stock increased 5.69% or $1.83 on November 23, hitting $33.98. About 559,694 shares traded hands or 110.40% up from the average. Repligen Corporation (NASDAQ:RGEN) has risen 21.40% since April 22, 2016 and is uptrending. It has outperformed by 15.99% the S&P500.
The move comes after 5 months positive chart setup for the $1.14B company. It was reported on Nov, 24 by We have $35.68 PT which if reached, will make NASDAQ:RGEN worth $57.00 million more.

Analysts await Repligen Corporation (NASDAQ:RGEN) to report earnings on February, 23. They expect $0.07 EPS, 0.00% or $0.00 from last year’s $0.07 per share. RGEN’s profit will be $2.35 million for 121.36 P/E if the $0.07 EPS becomes a reality. After $0.08 actual EPS reported by Repligen Corporation for the previous quarter, Wall Street now forecasts -12.50% negative EPS growth.

Repligen Corporation (NASDAQ:RGEN) Ratings Coverage

Out of 2 analysts covering Repligen (NASDAQ:RGEN), 1 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 50% are positive. Repligen has been the topic of 2 analyst reports since November 6, 2015 according to StockzIntelligence Inc. The company was initiated on Monday, February 22 by Craig Hallum. The stock of Repligen Corporation (NASDAQ:RGEN) has “Hold” rating given on Friday, November 6 by Jefferies.

According to Zacks Investment Research, “Repligen Corporation is a life sciences company focused on the development, production and commercialization of high-value consumable products used in the process of manufacturing biological drugs. Their bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. They are a leading manufacturer of Protein A, a critical reagent used to separate and purify monoclonal antibody therapeutics. They also supply several growth factor products used to increase cell culture productivity during the fermentation stage of drug manufacturing. In addition, they have developed and marketed their OPUS® series of pre-packed plug-and-play chromatography columns, and they provide test kits to ensure final product quality. Aside from their core bioprocessing business, they have a portfolio of clinical-stage partnering assets, including a pancreatic imaging agent in Phase 3 development and an orphan drug candidate in Phase 1 development.”

Insitutional Activity: The institutional sentiment decreased to 0.93 in Q2 2016. Its down 0.44, from 1.37 in 2016Q1. The ratio fall, as 18 funds sold all Repligen Corporation shares owned while 49 reduced positions. 20 funds bought stakes while 72 increased positions. They now own 29.03 million shares or 0.27% more from 28.95 million shares in 2016Q1.
Us Bankshares De holds 1,226 shares or 0% of its portfolio. Goldman Sachs Gp has invested 0% of its portfolio in Repligen Corporation (NASDAQ:RGEN). The Massachusetts-based Loomis Sayles And Co L P has invested 0% in Repligen Corporation (NASDAQ:RGEN). The Florida-based Eagle Asset Management has invested 0.04% in Repligen Corporation (NASDAQ:RGEN). Ladenburg Thalmann Inc, a Florida-based fund reported 9,018 shares. Pdt Partners Ltd Co last reported 44,200 shares in the company. Proshare Advisors holds 0.01% or 29,926 shares in its portfolio. Creative Planning reported 1,250 shares or 0% of all its holdings. The Illinois-based Envestnet Asset Management Incorporated has invested 0% in Repligen Corporation (NASDAQ:RGEN). Qs Invsts Limited Liability Company holds 0.04% or 159,214 shares in its portfolio. Comml Bank Of Montreal Can last reported 58,692 shares in the company. Quantbot Limited Partnership has 361 shares for 0% of their US portfolio. Franklin Street Advsr Nc reported 20,000 shares or 0.1% of all its holdings. Boston Advisors Ltd Limited Liability Company accumulated 0.01% or 13,755 shares. Rhumbline Advisers holds 60,271 shares or 0% of its portfolio.

Insider Transactions: Since June 30, 2016, the stock had 0 insider purchases, and 2 selling transactions for $220,989 net activity. Shares for $87,979 were sold by RYAN THOMAS F JR.

More important recent Repligen Corporation (NASDAQ:RGEN) news were published by: which released: “Virtual Stock Exchange” on November 16, 2010, also published article titled: “3 Important Things You Need to Know About Repligen Corporation’s Q3 Results”, published: “Read This Before You Sell Repligen Corporation Stock” on April 04, 2016. More interesting news about Repligen Corporation (NASDAQ:RGEN) was released by: and their article: “Why Repligen Corporation Shares Are Falling” with publication date: November 06, 2015.

RGEN Company Profile

Repligen Corporation, incorporated on May 29, 1981, is a bioprocessing company. The Firm is focused on the development, production and commercialization of products used in the process of manufacturing biologic drugs (bioprocessing). The Firm is a maker of both native and recombinant forms of Protein A, critical reagents used in biomanufacturing to separate and purify monoclonal antibodies, a type of biologic drug. It also supplies several growth factor products, Alternating Tangential Flow (ATF) System products and cell filtration products used to increase cell culture productivity during the bioproduction process. The Firm has developed a series of OPUS chromatography columns for use in clinical-scale manufacturing. The Firm makes and sells Protein A and growth factors to life sciences companies under long-term supply agreements and sells its chromatography columns, as well as media and quality test kits, and ATF products directly to biopharmaceutical companies or contract manufacturing organizations or through distributors. The Firm makes its products in production facilities in the United States and Sweden. The Firm markets its products globally through a direct commercial organization in the United States, Europe and Asia, as well as through strategic partners in select markets.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment